retatrutide type 2 diabetes phase 2 trial 2024 💉 may be redefining obesity treatment. New data from TRIUMPH-1 showed: 🔥 ~28% average weight loss over 80 weeks 🔥 >30% weight loss in nearly half of participant #ObesityMedicine #Retatrutide #GLP1 #CardioMetabolic 🚨Breaking: Retatrutide's first Phase 3

Originally, they considered that the risk of cardiovascular disease associated with obesity resulted in higher costs than covering these medications for weight loss

Retatrutide (LY-3437943) is an innovative research peptide that is increasingly gaining popularity within scientific communities across the UK and worldwide

This is because the body cant effectively use the insulin it produces

What works wonderfully for one person may not work for another

In a small phase 2 randomized clinical trial this year, adults with alcohol use disorder saw a reduction in their alcohol consumption and cravings after receiving a weekly semaglutide shot

This reduces drop-off rates and increases satisfaction, especially among users who have experienced burnout from past programs